Q-omics provides the consensus-scored PUDPP2 profile across patient tissues and cancer cell-line models. PUDPP2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PUDPP2 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, PUDPP2 RNA expression shows 7,025 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, and ESCA as cancer lineages where PUDPP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PUDPP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PUDPP2 survival associations across molecular data types. PUDPP2 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PUDPP2 RNA expression–survival associations across cancer types. High PUDPP2 expression shows unfavorable associations in BLCA, READ, LUAD and KIRC, but favorable associations in HNSC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PUDPP2 RNA expression.
This table summarizes PUDPP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PUDPP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PUDPP2 shows higher tumor expression in HNSC, KIRC, LUSC, THCA and LUAD. The HNSC box plot shows higher PUDPP2 RNA expression in tumor versus normal tissue (log2 FC = +0.285, t-test p = .001).
This table shows molecular features associated with PUDPP2 in patient tissues and cancer cell lines. In patient samples, PUDPP2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
